Affymax, (FRA:A5Y) Change In Receivables : €0.00 Mil (TTM As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Affymax, Change In Receivables?

Affymax,'s change in receivables for the quarter that ended in Jun. 2014 was €0.00 Mil. It means Affymax,'s Accounts Receivable stayed the same from Mar. 2014 to Jun. 2014 .

Affymax,'s change in receivables for the fiscal year that ended in Dec. 2013 was €13.41 Mil. It means Affymax,'s Accounts Receivable declined by €13.41 Mil from Dec. 2012 to Dec. 2013 .

Affymax,'s Accounts Receivable for the quarter that ended in Jun. 2014 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Affymax,'s Days Sales Outstanding for the three months ended in Jun. 2014 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Affymax,'s liquidation value for the three months ended in Jun. 2014 was €2.34 Mil.

Affymax, Change In Receivables Historical Data

The historical data trend for Affymax,'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Change In Receivables Chart

Affymax, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Change In Receivables

Get a 7-Day Free Trial

2.98

15.12

-5.27

-7.32

13.41

Affymax, Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Change In Receivables	Get a 7-Day Free Trial															0.67	-	-	-	-

Affymax, Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Affymax, (FRA:A5Y) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Affymax,'s Days Sales Outstanding for the quarter that ended in Jun. 2014 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.031	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Affymax,'s accounts receivable are only considered to be worth 75% of book value:

Affymax,'s liquidation value for the quarter that ended in Jun. 2014 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.502	-	0.158	+	0.75 * 0	+	0.5 * 0
=	2.34

Affymax, Change In Receivables Related Terms

Thank you for viewing the detailed overview of Affymax,'s Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax, (FRA:A5Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines